Advancing Care in Idiopathic Inflammatory Myopathies (IIMs): Bridging Knowledge Gaps and Exploring New Frontiers

Idiopathic inflammatory myopathies are a diverse, complex group of autoimmune diseases. Patients often wait a long time for a diagnosis, face toxicity from their treatment, and have needs that routine care doesn't fully address. As we learn more about disease subtypes, autoantibodies and targeted therapies, clinicians have more tools than ever to personalise care, and more evidence to keep up with.

In this 60-minute programme, experts Dr Victoria Werth, Dr Tahseen Mozaffar and Dr Rohit Aggarwal explain the latest thinking on IIM subtypes and immune mechanisms. They review the evidence for new and emerging therapies and give practical guidance on choosing the right treatment for the right patient.

Target Audience

Healthcare Professionals

Learning Objectives

  • Improved understanding of subtype-specific immune mechanisms and the role of autoantibodies in disease course and management.
  • Greater familiarity with evidence supporting new and emerging therapies; increased confidence in selecting appropriate patients for these treatments.
  • Increased recognition of diagnostic delays, treatment toxicity, and gaps in addressing patient-reported outcomes.

Activity Disclosures

This activity is supported by an educational grant from Argenx.

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
Course opens: 
03/13/2026
Course expires: 
03/12/2027
Cost:
$0.00
Dr Victoria Werth

Dr Victoria Werth

Dr Victoria Werth discloses the following: Consulting: Lilly, Pfizer, Biogen, BMS, Gilead, Amgen, EMD Sorona, CSL Behring, Crisalis, Argenx, Kwoya Kirin, Regeneron,AstraZeneca, Abbvie, GSK, UCB, Merck, Sanofi, Cabaletta Bio, Nuvig Pharmaceuticals, Takeda Pharmaceuticals, Immunovant, Anaptysbio, Evommune, Innovaderm, Boehringer Ingelheim Pharmaceuticals, Quotient Therapeutics, Duality Biologics, Glycoera, Almirall, Atticus,Inmagene, Exo, Novartis, Xencor, Architect Therapeutics, Celexor, Bimmunity​

Grants: Pfizer, Biogen, Gilead, Corbus Pharmaceuticals, AstraZeneca, Amgen, Regeneron, CSL Behring, Horizon, Priovant, Ventus, Viela,Glycoera, Chugai​

University of Pennsylvania owns the copyright for the CLASI and CDASI and DMOMS and IGA-DM and IGA-CLE​

Dr Tahseen Mozaffar

Dr Tahseen Mozaffar

Dr Tahseen Mozaffar discloses the following: Advisory roles: Alexion (Astra-Zeneca), Amicus, AnnJi, Argenx, Aro Bio, Ask-Bio, Audentes (now Astellas Gene Therapy), CreyonBio, Fate Therapeutics, Maze Therapeutics, Momenta (now Janssen), Regeneron, Sanofi, Shionogi, Spark Therapeutics, UCB/RaPharmaceuticals, Modis/Zogenix (now UCB), Variant Bio;  ​

Speakers Bureau: Sanofi-Genzyme ​

Medical Advisory Board: The Myositis Association, Neuromuscular Disease Foundation. ​

Research Funding: NIH, NCATS, TMA, Alexion, Amicus, AnnJi, Argenx, Ask Bio, Audentes/Astellas Gene Therapy, Aro Bio, Cabaletta, CartesianTherapeutics, Fate Therapeutics, ML-Bio, NKarta, Sanofi, Shionogi, Spark Therapeutics, UCB, and Ultragenyx. ​

Data Safety and Monitoring Boards: Applied Therapeutics, Sarepta, Sirolimus in IBM, and the NIH. ​

Dr Rohit Aggarwal

Dr Rohit Aggarwal

Dr Rohit Aggarwal discloses the following: Research grants: Boehringer Ingelheim (BI), Cabaletta Bio, Janssen, and PRoivant. ​

Consulting: Abcuro, Alexion, ANI Pharmaceutical, Argenx, Artiva Biotherapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers-Squibb,Cabaletta Bio, Capstanx, Century Therapeutics, CSL Behring, Dren Bio, EMD Serono, Fate Therapeutics Inc, Galapagos, GlaxoSmithKline LLC(GSK), Horizontal Therapeutics, Immunovant, Janssen, Janux Therapeutics, Kiniksa Pharmaceuticals, Lilly, Meiji Pharma,Novartis, Nkarta, Octapharma, OneFour Bio, Orna Therapeutics Inc, Ouro Medicines, Pfizer, PRoivant, SOBI, and Sun Pharmaceutical Industries.

All planners and reviewers involved in the development of this activity declared no relevant financial relationships with ineligible companies.

This activity underwent review in line with standards of editorial integrity and publication ethics. Potential conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest. The primary resolution method was review by an unconflicted expert. For information about the accreditation of this program, please contact [email protected].

John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

John Wiley and Sons, Inc. designates this enduring material based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within 60 minutes and complete the activity during the valid credit period, which is up to one year from initial publication. Additionally, up to 3 attempts and a score of 80% or higher is needed to pass the post-test and claim credit. You will need to log into your Wiley Health Learning account (registration is free) to complete this activity and earn a certificate.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™

Price

Cost:
$0.00
Please login or register to take this course.